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SUPPLEMENTARY METHODS 
 
SUBJECTS 
The initial GWA study included 1514 generalized vitiligo patients of North American and 
United Kingdom non-Hispanic/Latino white origin. All patients met strict clinical diagnostic 
criteria for generalized vitiligo
1
; subjects with other causes of localized hypopigmentation or 
uncertain diagnoses were excluded.   
The case-control replication study included 647 additional unrelated patients and 1056 
non-vitiligo controls of North American and European white origin, principally spouses of the 
vitiligo patients; all of these controls had no other known relatives with vitiligo.  The family-
based replication study included 183 unrelated simplex parents-affected offspring trios, and 332 
unrelated multiplex families, consisting of two or more affected family members and relevant 
unaffected relatives (1383 individuals), of North American and European non-Hispanic/Latino 
white origin. Patients, relatives, and controls in the two replication studies provided clinical 
history regarding vitiligo and other autoimmune diseases. 
Written informed consent was obtained from all study subjects. This study was approved 
by each institutional review board and was conducted according to Declaration of Helsinki 
principles. 
 
GENOTYPING AND QUALITY CONTROL 
Genomic DNA was prepared from peripheral-blood specimens by standard methods or from 
saliva specimens with use of a DNA self-collection kit using the manufacturer’s instructions 
(Oragene, DNA Genotek). DNA concentrations were assayed by ultraviolet A260 
spectrophotometry (NanoDrop, Thermo Scientific). Genomewide genotyping and quality control 
filtering of the genomewide genotyping data has been described elsewhere
2
. Briefly, we initially 
determined genotypes for approximately 610,000 SNPs in 1514 CEU GV cases using the 
Illumina 610-Quad BeadChip, and compared SNP allele frequencies to those of 2813 “public” 
controls genotyped using the Illumina 1M BeadChip, obtained from the Databases of Genotypes 
and Phenotypes (dbGaP) (n = 2731) and the Illumina iControlDB (n = 82). After stringent 
quality control filtering of SNP data and removal of genetic outliers and unmatchable individuals 
after genetic matching using GEM
3
, we performed unadjusted and eigenvector-adjusted 
Cochran-Armitage trend tests of the remaining 520,460 SNPs in the remaining 1392 cases and 
2629 controls using PLINK
4
 and EIGENSTRAT
5
, correcting test statistics for the remaining 
genomic inflation factor of 1.048 using the genomic control method
6
. 
Genotypes for additional SNPs across each of the candidate association regions were 
imputed from the GWA genotype dataset by use of MACH
7
, ver.1.0 
(http://www.sph.umich.edu/csg/abecasis/MACH/download/), based on  phased haplotype data in 
the HapMap
8
 CEU samples (phase II release 24, and phase III release 2). Only imputed 
genotypes with r
2
 > 0.3 were used for further analyses. 
In the present replication study we successfully determined genotypes for the most 
significant SNP from each of the seven loci that showed suggestive association in the initial 
GWA analysis, defined as nominal P values better than 10
-4
 for multiple SNPs across a 
contiguous genomic region, using the Sequenom MassArray iPLEX genotyping system. FOXP1 
SNP rs17008713 could not be genotyped using the MassArray system for technical reasons; 
accordingly, we imputed genotypes for nearby SNP rs17008723 (imputed genotype r
2
 = 0.995), 
which is in almost complete LD with rs17008713 in the GWA dataset (r
2 
= 0.99), and in the 
replication study we therefore genotyped rs17008723. Family-based data were subjected to 
Mendelian error-checking, and incompatibilities were either resolved or the incompatible 
individual or entire family was excluded. Two SNPs were excluded on the basis of apparent 
deviation from Hardy-Weinberg equilibrium in controls.  
 
STATISTICAL ANALYSES 
Statistical analyses of the GWA study have been described in detail elsewhere
2
. In the case-
control replication study, after quality control filtering, we compared allele frequencies for the 
remaining SNPs in 647 patients and 1056 controls using the Cochran-Armitage trend test
5
. Odds 
ratios and 95% confidence limits were calculated by logistic regression analysis. In the family-
based replication study, we calculated the association of each SNP with vitiligo using the family-
based association test (FBAT)
9
, version 1.5.5. Odds ratios (ORs) and 95% confidence limits were 
calculated by conditional logistic regression analysis, using matched case-pseudocontrol data 
derived from the family data
10
. To obtain combined P values and ORs, we performed meta-
analysis using a Cochran-Mantel-Haenszel test with cases and controls from the GWA study and 
the case-control replication study, and cases and pseudocontrols derived from the family-based 
dataset, and with just the two replication datasets. The fraction of variance accounted for by each 
of the confirmed GV association signals, and by all 12 loci combined, was calculated as Pseudo 
R
2
 by logistic regression analysis of the GWA and replication study case-control dataset using 
STATA, assuming a multiplicative model for each SNP
11
 and a polygenic multiplicative model 
for all 12 loci combined
12
.  
To test whether the P-values of the GV-associated CCR6 SNP rs6902119 and the Crohn’s 
disease-associated CCR6 SNP rs2301436 were independent of each other in the vitiligo data, we 
used STATA to compare the fit of the logistic regression model including both loci to a model 
including only the conditioning locus, assuming a multiplicative genotypic effect for the high-
risk allele of each locus.  
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)Supplementary Table 1      Suggestive Association of Seven Loci in the GWA Dataset
Chr SNP
nt Position 
(GRCh37 )
Risk 
Allele
Risk Allele Frequency EIGENSTRAT 
P value
PLINK        
P value
 Odds Ratio 
(95%CI)Cases Controls
3p13 rs11720980 71505650 A 0.371 0.324 5.30E‐05 4.03E‐05 1.23(1.12‐1.35)
rs6549391 71529915 A 0.710 0.674 1.00E‐03 1.20E‐03 1.19 (1.07‐1.31)
rs6549392 71538696 G 0.713 0.676 1.05E‐03 1.10E‐03 1.19 (1.07‐1.31)
rs11720523 71545170 C 0.619 0.575 2.40E‐04 1.91E‐04 1.2 0(1.09‐1.32)
rs6779258 71549639 T 0.618 0.571 9.57E‐05 8.12E‐05 1.21 (1.10‐1.33)
rs2133627 71551870 C 0.250 0.209 8.86E‐05 5.54E‐05 1.26 (1.13‐1.40)
rs17008713 71566417 T 0.215 0.172 6.28E‐06 3.70E‐06 1.32 (1.18‐1.48)
rs9866496 71568501 C 0.282 0.236 1.36E‐05 1.04E‐05 1.27 (1.15‐1.41)
rs1499895 71571667 A 0.607 0.563 2.34E‐04 2.04E‐04 1.20(1.09‐1.32)
3q13.13 rs697963 107078487 T 0.992 0.982 9.58E‐04 9.08E‐04 2.18 (1.38‐3.46)
rs6779094 108081277 A 0.257 0.215 3.47E‐05 3.96E‐05 1.26 (1.13‐1.41)
rs11707076 108098637 T 0.292 0.255 5.02E‐04 4.61E‐04 1.21 (1.09‐1.34
rs10511271 108114572 C 0.246 0.212 3.30E‐04 4.79E‐04 1.22 (1.09‐1.36)
rs4273371 108119071 T 0.549 0.500 7.12E‐05 4.95E‐05 1.22 (1.11‐1.33)
rs9810676 108132759 T 0.500 0.457 3.80E‐04 3.01E‐04 1.19 (1.09‐1.31)
rs3996020 108179729 A 0.347 0.293 2.02E‐06 1.15E‐06 1.28 (1.16‐1.42)
rs4299484 108189627 T 0.344 0.289 1.58E‐06 9.86E‐07 1.29 (1.17‐1.42)
rs2603127 108243551 A 0.265 0.213 4.50E‐07 2.69E‐07 1.34 (1.20‐1.49)
rs6784002 108260695 A 0.555 0.516 1.39E‐03 9.30E‐04 1.17 (1.07‐1.29)
rs2060986 108264948 T 0.394 0.355 1.26E‐03 8.90E‐04 1.18 (1.07‐1.30)
rs7633235 108454848 T 0.237 0.191 2.46E‐06 1.19E‐06 1.33 (1.19‐1.49)
rs9815057 108464197 T 0.234 0.189 6.59E‐06 3.83E‐06 1.31 (1.17‐1.47)
rs7637614 108508966 G 0.557 0.515 5.94E‐04 4.43E‐04 1.19 (1.08‐1.30)
rs9879707 108580778 A 0.191 0.157 2.25E‐04 1.50E‐04 1.27 (1.13‐1.44)
6q27 rs1358786 166054922 A 0.148 0.121 7.83E‐04 1.02E‐03 1.25 (1.10‐1.43)
rs11755875 166216338 C 0.808 0.775 6.41E‐04 7.55E‐04 1.22 (1.09‐1.37)
rs9366076 167373708 C 0.818 0.787 7.15E‐04 1.52E‐03 1.21 (1.08‐1.36)
rs9355610 167383075 G 0.711 0.672 2.99E‐04 6.33E‐04 1.19 (1.08‐1.32)
rs429083 167383972 G 0.581 0.543 8.38E‐04 1.34E‐03 1.17 (1.07‐1.28)
rs9366078 167399512 A 0.709 0.671 3.43E‐04 7.29E‐04 1.19 (1.08‐1.32)
)rs933243 167403873 G 0.709 0.671 3.26E‐04 7.01E‐04 1.19 (1.08‐1.32)
rs400837 167411008 C 0.581 0.543 9.36E‐04 1.47E‐03 1.17(1.06‐1.28)
rs2301436 167437988 A 0.524 0.479 2.41E‐04 2.27E‐04 1.19 (1.09‐1.30)
rs12529876 167461501 A 0.464 0.419 1.91E‐04 1.68E‐04 1.20 (1.09‐1.31)
rs10484530 167461562 A 0.446 0.405 6.61E‐04 6.16E‐04 1.18 (1.08‐1.29)
rs12183084 167473685 G 0.446 0.404 5.82E‐04 5.47E‐04 1.18 (1.08‐1.29)
rs6921588 167494397 A 0.462 0.419 4.00E‐04 3.65E‐04 1.19(1.08‐1.29)
rs204295 167500562 C 0.580 0.540 8.91E‐04 9.84E‐04 1.17 (1.07‐1.28)
rs6902119 167505791 C 0.495 0.446 7.23E‐05 5.72E‐05 1.21 (1.11‐1.33)
rs6456156 167522300 C 0.541 0.502 1.59E‐03 1.57E‐03 1.16 (1.06‐1.27)
rs4708777 167814784 A 0.922 0.904 2.86E‐03 1.71E‐03 1.32 (1.11‐1.56)
7p21.3 rs2192346 8176301 A 0.778 0.737 5.40E‐05 6.59E‐05 1.26 (1.13‐1.40)
rs887848 8179846 A 0.756 0.722 1.23E‐03 1.37E‐03 1.20 (1.07‐1.33)
rs2110333 8185089 T 0.755 0.719 6.77E‐04 8.00E‐04 1.20 (1.08‐1.34)
9q22.33 rs7870439 100951838 G 0.778 0.744 9.81E‐04 1.02E‐03 1.21 (1.08‐1.34)
rs10818610 100969348 G 0.654 0.612 5.02E‐04 4.12E‐04 1.19 (1.08‐1.31
rs7868451 100987622 A 0.695 0.650 6.80E‐05 8.37E‐05 1.22 (1.11‐1.35)
rs1573025 100991430 G 0.838 0.804 2.63E‐04 2.40E‐04 1.26 (1.12‐1.42)
rs879368 100995758 C 0.748 0.705 8.42E‐05 9.23E‐05 1.24 (1.11‐1.37)
rs7853442 101008885 A 0.693 0.649 8.94E‐05 1.08E‐04 1.22 (1.10‐1.34)
rs10115971 101024887 A 0.834 0.801 6.61E‐04 6.36E‐04 1.24 (1.10‐1.39)
rs10818692 101026301 A 0.834 0.801 5.48E‐04 5.37E‐04 1.24 (1.10‐1.39)
rs10760233 101034626 G 0.745 0.708 7.61E‐04 7.43E‐04 1.20  (1.08‐1.32)
rs4743196 101049252 G 0.662 0.623 6.63E‐04 8.05E‐04 1.18 (1.07‐1.29)
12q13.2 rs11171710 56368078 G 0.582 0.541 5.10E‐04 4.94E‐04 1.19 (1.08‐1.30)
rs773107 56369506 G 0.376 0.319 1.03E‐06 6.60E‐07 1.28 (1.17‐1.41)
rs10876864 56401085 G 0.467 0.411 5.57E‐06 2.74E‐06 1.25 (1.14‐1.37)
rs1701704 56412487 C 0.389 0.329 2.54E‐07 1.66E‐07 1.30 (1.18‐1.42)
rs705708 56488913 A 0.507 0.463 1.53E‐04 2.15E‐04 1.20 (1.09‐1.31)
rs10783779 56491880 G 0.445 0.405 4.34E‐04 6.25E‐04 1.18 (1.08‐1.30)
12q24.12 rs12311063 110557312 A 0.656 0.619 1.49E‐03 1.73E‐03 1.17 (1.06‐1.29)
rs12313068 110597304 C 0.865 0.836 9.70E‐04 6.98E‐04 1.26(1.11‐1.44)
rs11065287 110609714 T 0.342 0.296 8.82E‐05 3.53E‐05 1.24 (1.12‐1.36)
rs12318836 110642190 A 0.883 0.855 7.49E‐04 4.76E‐04 1.29 (1.12‐1.48)
yrs10774599 110697448 T 0.667 0.630 2.67E‐03 1.53E‐03 1.17 (1.07‐1.29)
rs3026445 110723203 T 0.669 0.631 4.25E‐04 1.26E‐03 1.18 (1.07‐1.29)
rs7957299 111002311 G 0.361 0.319 3.81E‐04 1.83E‐04 1.21 (1.10‐1.34)
rs7975139 111221131 T 0.908 0.884 1.64E‐03 1.24E‐03 1.30 (1.11‐1.52)
rs850511 111239821 A 0.482 0.441 9.50E‐04 4.84E‐04 1.19 (1.08‐1.30)
rs7970490 111756438 A 0.741 0.701 4.75E‐04 3.60E‐04 1.21 (1.09‐1.34)
rs3847953 111765464 G 0.747 0.711 1.32E‐03 1.12E‐03 1.19 (1.07‐1.31)
rs3184504 111884608 T 0.544 0.490 1.47E‐05 6.91E‐06 1.24 (1.13‐1.36)
rs653178 112007756 G 0.545 0.492 2.05E‐05 9.58E‐06 1.24 (1.13‐1.35)
rs11065987 112072424 G 0.475 0.432 6.75E‐04 3.72E‐04 1.19 (1.08‐1.30)
rs17696736 112486818 G 0.480 0.440 1.41E‐03 8.22E‐04 1.17 (1.07‐1.28)
rs11066188 112610714 A 0.462 0.423 2.13E‐03 1.23E‐03 1.17 (1.07‐1.28)
rs11066320 112906415 A 0.475 0.436 2.28E‐03 1.42E‐03 1.17 (1.06‐1.27)
rs233716 113039943 G 0.437 0.397 1.85E‐03 9.82E‐04 1.17 (1.07‐1.28)
Listed SNPs are from the 2000 with highest‐ranked PLINK P values in the GWA stud
Supplementary Table 2  Genotype counts for SNPs in novel candidate GV susceptibility 
loci  
 
SNP GWA Study Replication 1 Replication 2 
 
Chr 
Locus 
Region 
 
ID 
Location 
(nt) 
Genotypes  
Cases 
 
Controls Cases Controls 
 
Cases 
          
Replicated 
loci 
         
3p13 FOXP1 rs17008713 71566417 
 
     
    GG 61 (4.4) 83 (3.1) 25 (4.1) 25 (2.8) 30 (3.2) 
    GT 476 (34.2) 735 (28.0) 210 (34.8) 253 (28.3) 313 (33.6) 
    TT 855 (61.4) 1811 (68.9) 369 (61.1) 617 (68.9) 590 (63.2) 
6q27 CCR6 rs6902119 167505791       
    CC 361 (25.9) 527 (20.0) 124 (21.3) 158 (18.9) 243 (24.9) 
    CT 655 (47.1) 1290 (49.1) 353 (60.5) 459 (54.8) 495 (50.7) 
    TT 376 (27.0) 812 (30.9) 106 (18.2) 220 (26.3) 239 (24.4) 
Unconfirmed 
loci 
         
3q13.13 MYH15 rs2603127 108243551       
    AA 92 (6.6) 118 (4.5) 20 (3.5) 30 (3.6) 67 (7.6) 
    AG 553 (39.7) 880 (33.5) 167 (28.8) 217 (26.1) 285 (32.2) 
    GG 747 953.7) 1624 (61.9) 392 (67.7) 585 (70.3) 533 (60.2) 
Excluded 
loci 
         
7p21.3 ICA1 rs2192346 8176301       
    AA 840 (60.4) 1413 (53.8) 347 (57.0) 513 (57.6) 581 (59.8) 
    AG 485 (34.9) 1049 (39.9) 221 (36.3) 332 (37.3) 350 (36.1) 
    GG 66 (4.7) 166 (6.3) 40 (6.6) 45 (5.1) 40 (4.1) 
9q22.33 TBC1D2 rs7868451 100987622       
    AA 686 (49.3) 1127 (42.9) 214 (37.3) 370 (46.8) 418 (44.0) 
    AG 563 (40.4) 1162 (44.2) 288 (50.3) 332 (42.0) 422 (44.5) 
    GG 143 (10.3) 340 (12.9) 71 (12.4) 88 (11.1) 109 (11.5) 
Supplementary Table 3 Replication analysis of novel candidate GV susceptibility loci – Excluded loci 
 
 
 
GWA Study  Replication 1  Replication 2 
 Meta-analysis 
Replication 1 + Replication 2 
 Meta-analysis 
GWA + Replication 1 + Replication 2 
SNP 
Risk 
allele 
AFRA, 
cases 
AFRA, 
controls 
PLINK P OR 
 
P OR 
 
P OR 
 
P OR 
 
P OR 
rs2192346 A 0.778 0.734 6.59 x 10-5 1.26  0.510 0.94  0.572 0.90  0.627 0.96  1.42 x 10-3 1.16 
rs7868451 A 0.695 0.650 8.37 x 10-5 1.22  3.45 x 10-3 0.79  0.346 1.01  0.016 0.82  0.022 1.10 
 
SNP rs2192346 and rs7868451 were located at nt 8,176,301in the ICA1 region of 7p21.3, and nt 100,987,622 in the TBC1D2 region of 9q22.33, respectively. SNP nucleotide 
positions are from GRCh37 and genes in close proximity to the designated SNP are denoted. AFRA, allele frequency of the risk allele EIGENSTRAT GWA P-values for SNPs 
rs2192346 and rs7868451 were 5.40 x 10
-5
, and 6.80 x 10
-5
, respectively. PLINK and EIGENSTRAT GWA test statistics were calculated and adjusted for the genomic inflation 
factor 1.048 as described in the Supplementary Methods. The Bonferroni adjusted significance threshold for the combined replication stage 1 + 2 meta-analysis was P < 1.00 x 10
-2
, 
and the significance threshold for the overall combined GWA + replication stage 1 + 2 meta-analysis was P < 5 x 10
-8
.  
 
 
 
